A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew H. Ko, MD
University of California, San Francisco
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Honorhealth Research Institute
Scottsdale, Arizona, United States
- Hoag Medical Group
Newport Beach, California, United States
- Ucsf Medical Center
San Francisco, California, United States
- Ucla Hematology/oncology, Gastrointestinal Oncology
Santa Monica, California, United States
- University Cancer and Blood Center
Athens, Georgia, United States
- Community Health Network
Indianapolis, Indiana, United States
- Norton Cancer Institute Audubon
Louisville, Kentucky, United States
- University Medical Center New Orleans
New Orleans, Louisiana, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Clinical Research Alliance
Westbury, New York, United States
- Penn State Hershey Cancer Institute
Hershey, Pennsylvania, United States
- the University of Texas Southwestern Medical Center
Dallas, Texas, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Utah Cancer Specialists
Salt Lake City, Utah, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Aug 2022
- Primary completion
- 30 Jun 2026
- Completion
- 31 Jul 2026
- Last update posted
- 19 Dec 2025
- Registered enrollment
- 70
- Registry id
- NCT05249101
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.